* Drug meets primary endpoint in mid-stage trial
* Shares rise 39 pct before the bell
May 27 (Reuters) - CombinatoRx Inc CRXX.O said its anti-diabetic treatment met its primary goal in a mid-stage trial, sending the biopharmaceutical company's shares up 39 percent in pre-market trade.
The primary endpoint of the study found the drug, a combination of bezafibrate and diflunisal, performed significantly better than bezafibrate in reducing fasting plasma glucose and showed a positive trend in other efficacy measures, the company said.
The study, which enrolled 120 people with moderate to severe diabetes, tested the drug as an add-on to metformin therapy in Type 2 diabetes.
The drug, code named CRx-401, is an insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain.
Shares of the company were up 39 percent at 96 cents before the bell. They closed at 69 cents Tuesday on Nasdaq.
For related alerts, please double click [ID:nWNAB3686] (Reporting by Shailesh Kuber in Bangalore; Editing by Gopakumar Warrier)
Our Standards: The Thomson Reuters Trust Principles.